ImmunoPET imaging for pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on using ImmunoPET imaging to evaluate the distribution of a targeted therapy for pancreatic cancer. Patients with confirmed or suspected pancreatic cancer will receive a radiolabeled antibody, SHR1920, which will be tracked using PET scans to assess its uptake in tumors and normal tissues. The study aims to determine the diagnostic efficacy of this imaging technique and its correlation with protein expression levels in tumors. By identifying patients who are more likely to benefit from targeted therapies, the study seeks to enhance treatment outcomes for pancreatic cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed diagnosis of pancreatic cancer or suspected pancreatic cancer by diagnostic imaging.
* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria:

* Known or suspected hypersensitivity to SHR1920, DFO/RESCA/NOTA, 89Zr/18F or 68Ga or any of the excipients.
* Pregnancy

Where it's running

• Renji Hospital, School of Medicine, Shanghai Jiao Tong University
  Shanghai, China Recruiting

Study contacts

• Principal investigator: Weijun Wei, Ph.D. & M.D. — Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
• Study coordinator: Weijun Wei, Ph.D. & M.D.
• Email: wwei@shsmu.edu.cn
• Phone: 15000083153

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Plasma DNA Methylation to Classify Kidney Masses Before Surgery

  This study tests a blood-based DNA methylation test to help distinguish malignant kidney cancers from benign kidney masses in adults who are planned for kidney surgery.

  Recruiting RenJi Hospital · Shanghai, Shanghai Municipality · NCT07874542

• miRNA panel test to help diagnose prostate cancer

  A blood test using a microRNA panel is being tested to help diagnose prostate cancer in men who are suspected of having the disease.

  Recruiting RenJi Hospital · Shanghai · NCT07755592

• Comparing ClotTriever vs. aspiration thrombectomy for acute iliofemoral DVT

  This study tests whether the ClotTriever System clears clot better than aspiration thrombectomy in adults with acute iliofemoral deep vein thrombosis.

  Recruiting RenJi Hospital · Shanghai · NCT07622212

• Profunda Femoris Vein Thrombosis Clearance to Improve Outcomes of Endovascular Treatment

  This trial tests whether clearing a blockage in the profunda femoris vein during endovascular treatment helps keep the iliofemoral vein open and reduces post-thrombotic syndrome in adults with acute iliofemoral DVT.

  Recruiting RenJi Hospital · Shanghai · NCT07622199

• Growth and development in infants after liver transplant

  We will track how babies up to 1 year old grow and develop over time after a liver transplant to find patterns that can improve follow-up care.

  Recruiting RenJi Hospital · Shanghai, Shanghai Municipality · NCT07574398

• Acute pancreatitis after percutaneous mechanical thrombectomy: a retrospective analysis

  This project will look at adult medical records to see how often acute pancreatitis happens after percutaneous mechanical thrombectomy for thrombotic peripheral vascular disease.

  Recruiting RenJi Hospital · Shanghai, Shanghai Municipality · NCT07450898

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.